Both are FDA-approved for weight management. But which one is right for your body, your goals, and your stage of life?
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two dominant GLP-1-based therapies for weight management. Both have strong clinical evidence. The key difference: semaglutide targets one receptor (GLP-1), while tirzepatide targets two (GLP-1 + GIP) — and that dual mechanism translates to greater weight loss in head-to-head trials.
But weight loss numbers aren't the whole story for women. PCOS, menopause metabolism, side effect tolerance, cost, and access all factor in.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist (single receptor) | GLP-1 + GIP dual agonist |
| Weight Loss | 15-17% body weight (STEP trials) | Up to 22.5% (SURMOUNT-1) |
| FDA Status | Approved (Wegovy for weight, Ozempic for diabetes) | Approved (Zepbound for weight, Mounjaro for diabetes) |
| Oral Option | Yes — Wegovy pill launched Jan 2026 | Not yet (in development) |
| Insulin Sensitivity | Significant improvement | Superior improvement (dual mechanism) |
| PCOS Relevance | Strong — improves insulin resistance | Potentially stronger — dual agonism may better address PCOS insulin dysregulation |
| Nausea | Common during titration (~45%) | Similar rates, some reports of less severity |
| Lean Mass | Some lean mass loss during weight reduction | GIP component may better preserve lean mass |
| Time on Market | Longer track record (approved 2021) | Newer (approved 2023) |
| Cost (cash pay) | ~$1,000-1,300/mo branded | ~$1,000-1,100/mo branded |
Both improve insulin sensitivity, but tirzepatide's dual mechanism may offer an edge. The GIP component contributes to metabolic efficiency beyond appetite suppression — potentially more relevant for PCOS, where insulin resistance is the root driver rather than appetite alone. That said, semaglutide has more published data specifically in PCOS populations.
The metabolic shift during menopause is driven by estrogen decline, reduced metabolic rate, and changes in fat distribution. Both peptides address appetite and metabolism, but tirzepatide's greater overall efficacy (22.5% vs 15-17%) may be more appropriate for women experiencing treatment-resistant menopausal weight gain. The emerging evidence on lean mass preservation is also relevant — menopausal women are already at risk for sarcopenia.
Choose semaglutide if: you want an oral option, a longer safety track record, or are on a tighter budget with compounding options. Choose tirzepatide if: maximum weight loss is the priority, PCOS insulin resistance is a primary concern, or previous GLP-1-only therapy plateaued.
Yes — many patients switch under provider guidance, typically when weight loss plateaus on semaglutide. Your provider will advise on titration schedules for the transition.
GI side effects (nausea, vomiting, diarrhea) are similar for both. Some clinicians report tirzepatide may cause less severe nausea, but this varies by individual. Both improve with dose titration.
The availability of compounded versions depends on current FDA shortage status and regulations. As of 2026, the regulatory landscape is evolving. Check with your provider and vendor for current availability.
Medical Disclaimer: This comparison is for educational purposes only. Both semaglutide and tirzepatide are prescription medications that should only be used under medical supervision. Individual results and appropriate therapy depend on your specific health profile. Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Our quiz considers your life stage, goals, and preferences to recommend the best fit.
Take the Quiz →